VAC-1

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameVAC-1
Drug Alias NamehTERT RNA vaccine - Argos/GeronAntigen-presenting autologous dendritic cells - Lineage Cell TherapeuticsRNA-loaded autologous dendritic cell vaccine - Argos/GeronCancer vaccine (Argos Therapeutics Inc/Geron)Antigen-presenting allogeneic dendritic cells +[11] 
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionHuman telomerase (hTERT)-directed cytolytic effectsImmunostimulants
TargetsTelomerase reverse transcriptase
Therapy Area/IndicationsProstatic NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGeron CoArgos Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAsterias Biotherapeutics IncUniversity Of Florida
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A